EX-23 3 ex23-2.htm CONSENT ex23-2
Exhibit 23.2
We hereby consent to the incorporation by reference in this Form S-3 to be filed on or about February 1, 2021 constituting part of the Registration Statement on Form S-3 of our report dated March 30, 2020, related to the consolidated financial statements of AzurRx BioPharma, Inc. as of December 31, 2019 and 2018 and for the years then ended, which appears in the Annual Report on Form 10-K of AzurRx BioPharma, Inc. for the year ended December 31, 2019. The report for AzurRx BioPharma, Inc. includes an explanatory paragraph about the existence of substantial doubt concerning its ability to continue as a going concern. We also consent to the reference to our Firm under the caption “Experts” in this Form S-3.
/s/ Mazars USA LLP
New York, New York
February 1, 2021